{"id":79178,"date":"2026-09-07T12:12:03","date_gmt":"2026-09-07T04:12:03","guid":{"rendered":"https:\/\/flcube.com\/?p=79178"},"modified":"2026-09-07T12:12:04","modified_gmt":"2026-09-07T04:12:04","slug":"jenscares-lux-valve-plus-wins-hong-kong-approval-expanding-global-footprint-of-transcatheter-tricuspid-valve-replacement-system","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=79178","title":{"rendered":"Jenscare&#8217;s LuX\u2011Valve Plus Wins Hong Kong Approval, Expanding Global Footprint of Transcatheter Tricuspid Valve Replacement System"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Ningbo Jenscare Scientific Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/9877:HKG\">HKG: 9877<\/a>) announced that its transcatheter tricuspid valve replacement system, <strong>LuX\u2011Valve Plus<\/strong>, was recently approved for commercialization by the <strong>Department of Health of the Hong Kong Special Administrative Region<\/strong>. The clearance marks the latest regulatory win for the world&#8217;s second approved transcatheter orthotopic tricuspid valve replacement product.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Field<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td>Agency<\/td><td><strong>Department of Health, Hong Kong Special Administrative Region<\/strong><\/td><\/tr><tr><td>Approval Type<\/td><td>Commercialization approval<\/td><\/tr><tr><td>Product<\/td><td><strong>LuX\u2011Valve Plus<\/strong> transcatheter tricuspid valve replacement system<\/td><\/tr><tr><td>Indication<\/td><td>Tricuspid valve disease (orthotopic transcatheter tricuspid valve replacement)<\/td><\/tr><tr><td>Company<\/td><td><strong>Ningbo Jenscare Scientific Co., Ltd.<\/strong> (HKG: 9877)<\/td><\/tr><tr><td>Date<\/td><td>04 Sep 2026<\/td><\/tr><tr><td>Next Steps<\/td><td>Continued clinical promotion and commercial expansion across approved markets<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-product-profile-amp-differentiation\" class=\"wp-block-heading\">Product Profile &amp; Differentiation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Device:<\/strong> <strong>LuX\u2011Valve Plus<\/strong>, a transcatheter orthotopic tricuspid valve replacement system.<\/li>\n\n\n\n<li><strong>Global Standing:<\/strong> The world&#8217;s second approved transcatheter orthotopic tricuspid valve replacement product.<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> The company cites differentiated product advantages as a key driver of market adoption.<\/li>\n\n\n\n<li><strong>Clinical Foundation:<\/strong> Extensive clinical application experience accumulated to date supports ongoing commercialization.<\/li>\n\n\n\n<li><strong>Market Recognition:<\/strong> Broad recognition gained through continuous clinical promotion efforts.<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-commercial-footprint-global-regulatory-approvals\" class=\"wp-block-heading\">Commercial Footprint \u2013 Global Regulatory Approvals<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Region<\/th><th>Status<\/th><\/tr><\/thead><tbody><tr><td>Greater China (incl. Hong Kong SAR)<\/td><td>Commercialization approval granted by the <strong>Department of Health of the Hong Kong SAR<\/strong><\/td><\/tr><tr><td>Europe<\/td><td>Regulatory approvals obtained in multiple countries<\/td><\/tr><tr><td>Middle East<\/td><td>Regulatory approvals obtained<\/td><\/tr><tr><td>Asia\u2011Pacific<\/td><td>Regulatory approvals obtained in multiple countries and regions<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">With the Hong Kong approval, <strong>LuX\u2011Valve Plus<\/strong> has now secured regulatory clearances across multiple countries and regions in Europe, the Middle East, and the Asia\u2011Pacific region \u2014 building a diversified international footprint for the transcatheter tricuspid valve replacement platform.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Category Position:<\/strong> As one of only two approved transcatheter orthotopic tricuspid valve replacement products worldwide, <strong>LuX\u2011Valve Plus<\/strong> holds first\u2011mover positioning in a rapidly emerging structural heart category.<\/li>\n\n\n\n<li><strong>International Expansion:<\/strong> Approvals spanning Europe, the Middle East, and Asia\u2011Pacific broaden the addressable market and reduce single\u2011region dependence.<\/li>\n\n\n\n<li><strong>Adoption Drivers:<\/strong> Differentiated design advantages, established clinical experience, and active clinical promotion underpin market recognition.<\/li>\n\n\n\n<li><strong>Growth Trajectory:<\/strong> Continued regulatory and commercial momentum positions <strong>Jenscare<\/strong> to scale <strong>LuX\u2011Valve Plus<\/strong> adoption in underserved tricuspid valve disease populations.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong> \u2014 This brief contains forward\u2011looking statements regarding <strong>Ningbo Jenscare Scientific Co., Ltd.<\/strong>&#8216;s commercialization of <strong>LuX\u2011Valve Plus<\/strong> and its ongoing regulatory and market expansion for transcatheter tricuspid valve replacement. Such statements are based on current expectations and are subject to risks and uncertainties, including regulatory review, market acceptance, and commercialization risks. Actual results may differ materially. Nothing herein constitutes investment advice or an offer to buy or sell any securities.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/2026090402516_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026090402516_c.\"><\/object><a id=\"wp-block-file--media-c83f6dda-fb6d-4057-a2d5-5292f7105a78\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/2026090402516_c.pdf\">2026090402516_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/2026090402516_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-c83f6dda-fb6d-4057-a2d5-5292f7105a78\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Ningbo Jenscare Scientific Co., Ltd. (HKG: 9877) announced that its transcatheter tricuspid valve replacement system,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,22],"tags":[69,1300,583,15],"class_list":["post-79178","post","type-post","status-publish","format-standard","hentry","category-company","category-medical-device","tag-cvd","tag-hkg-9877","tag-jenscare-scientific","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Jenscare&#039;s LuX\u2011Valve Plus Wins Hong Kong Approval, Expanding Global Footprint of Transcatheter Tricuspid Valve Replacement System - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Ningbo Jenscare Scientific Co., Ltd. (HKG: 9877) announced that its transcatheter tricuspid valve replacement system, LuX\u2011Valve Plus, was recently approved for commercialization by the Department of Health of the Hong Kong Special Administrative Region. The clearance marks the latest regulatory win for the world&#039;s second approved transcatheter orthotopic tricuspid valve replacement product.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=79178\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Jenscare&#039;s LuX\u2011Valve Plus Wins Hong Kong Approval, Expanding Global Footprint of Transcatheter Tricuspid Valve Replacement System\" \/>\n<meta property=\"og:description\" content=\"Ningbo Jenscare Scientific Co., Ltd. (HKG: 9877) announced that its transcatheter tricuspid valve replacement system, LuX\u2011Valve Plus, was recently approved for commercialization by the Department of Health of the Hong Kong Special Administrative Region. The clearance marks the latest regulatory win for the world&#039;s second approved transcatheter orthotopic tricuspid valve replacement product.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=79178\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-07T04:12:03+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-07T04:12:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=79178#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=79178\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Jenscare&#8217;s LuX\u2011Valve Plus Wins Hong Kong Approval, Expanding Global Footprint of Transcatheter Tricuspid Valve Replacement System\",\"datePublished\":\"2026-09-07T04:12:03+00:00\",\"dateModified\":\"2026-09-07T04:12:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=79178\"},\"wordCount\":447,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"CVD\",\"HKG: 9877\",\"Jenscare Scientific\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Medical Device\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=79178#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=79178\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=79178\",\"name\":\"Jenscare's LuX\u2011Valve Plus Wins Hong Kong Approval, Expanding Global Footprint of Transcatheter Tricuspid Valve Replacement System - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-09-07T04:12:03+00:00\",\"dateModified\":\"2026-09-07T04:12:04+00:00\",\"description\":\"Ningbo Jenscare Scientific Co., Ltd. (HKG: 9877) announced that its transcatheter tricuspid valve replacement system, LuX\u2011Valve Plus, was recently approved for commercialization by the Department of Health of the Hong Kong Special Administrative Region. The clearance marks the latest regulatory win for the world's second approved transcatheter orthotopic tricuspid valve replacement product.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=79178#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=79178\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=79178#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Jenscare&#8217;s LuX\u2011Valve Plus Wins Hong Kong Approval, Expanding Global Footprint of Transcatheter Tricuspid Valve Replacement System\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Jenscare's LuX\u2011Valve Plus Wins Hong Kong Approval, Expanding Global Footprint of Transcatheter Tricuspid Valve Replacement System - Insight, China&#039;s Pharmaceutical Industry","description":"Ningbo Jenscare Scientific Co., Ltd. (HKG: 9877) announced that its transcatheter tricuspid valve replacement system, LuX\u2011Valve Plus, was recently approved for commercialization by the Department of Health of the Hong Kong Special Administrative Region. The clearance marks the latest regulatory win for the world's second approved transcatheter orthotopic tricuspid valve replacement product.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=79178","og_locale":"en_US","og_type":"article","og_title":"Jenscare's LuX\u2011Valve Plus Wins Hong Kong Approval, Expanding Global Footprint of Transcatheter Tricuspid Valve Replacement System","og_description":"Ningbo Jenscare Scientific Co., Ltd. (HKG: 9877) announced that its transcatheter tricuspid valve replacement system, LuX\u2011Valve Plus, was recently approved for commercialization by the Department of Health of the Hong Kong Special Administrative Region. The clearance marks the latest regulatory win for the world's second approved transcatheter orthotopic tricuspid valve replacement product.","og_url":"https:\/\/flcube.com\/?p=79178","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-09-07T04:12:03+00:00","article_modified_time":"2026-09-07T04:12:04+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=79178#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=79178"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Jenscare&#8217;s LuX\u2011Valve Plus Wins Hong Kong Approval, Expanding Global Footprint of Transcatheter Tricuspid Valve Replacement System","datePublished":"2026-09-07T04:12:03+00:00","dateModified":"2026-09-07T04:12:04+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=79178"},"wordCount":447,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["CVD","HKG: 9877","Jenscare Scientific","Product approvals"],"articleSection":["Company","Medical Device"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=79178#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=79178","url":"https:\/\/flcube.com\/?p=79178","name":"Jenscare's LuX\u2011Valve Plus Wins Hong Kong Approval, Expanding Global Footprint of Transcatheter Tricuspid Valve Replacement System - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-09-07T04:12:03+00:00","dateModified":"2026-09-07T04:12:04+00:00","description":"Ningbo Jenscare Scientific Co., Ltd. (HKG: 9877) announced that its transcatheter tricuspid valve replacement system, LuX\u2011Valve Plus, was recently approved for commercialization by the Department of Health of the Hong Kong Special Administrative Region. The clearance marks the latest regulatory win for the world's second approved transcatheter orthotopic tricuspid valve replacement product.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=79178#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=79178"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=79178#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Jenscare&#8217;s LuX\u2011Valve Plus Wins Hong Kong Approval, Expanding Global Footprint of Transcatheter Tricuspid Valve Replacement System"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/79178","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=79178"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/79178\/revisions"}],"predecessor-version":[{"id":79182,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/79178\/revisions\/79182"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=79178"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=79178"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=79178"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}